Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for prevention of chemotherapy-related cognitive impairment in breast cancer
IRCT20250410065283N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in postchemotherapy cognitive impairment (CRCI) comparing Memantine + usual chemotherapy with Placebo + usual chemotherapy (2 arms). Primary endpoint: Frequency of chemotherapy-induced cognitive impairment. Started Jul 2025; status: completed.
02
Drugs
memantine
03
Conditions
postchemotherapy cognitive impairment (CRCI)
Beyond the preview
Go deeper on IRCT20250410065283N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250410065283N1.